In perspective, the development of an accurate prediction model based on a wide range of pharmacogenetic, metabolic [55], clinical [56], circulating microRNA [57,58], and serological [59] markers—which may influence the treatment response with an additive score significance—could tailor better personalized anti-TNF-α treatments for RA patients. This evidence concerns the gene TNF and rheumatoid arthritis.